Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PULM

Pulmatrix Inc

Feb 06 • 04:00PM ET

2.48

-0.01 -0.40 %

Healthcare • Biotechnology • USA • NASD

Peers: AXSM ACHV BLRX AKBA ACRS CLSD ASMB ACET ARDX ALDX

| Held by: VXF DFAC DCOR DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.70	Insider Own	0.00%	Shs Outstand	3.65M	Perf Week	-3.50%
Market Cap	9.06M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	3.65M	Perf Month	7.83%
Enterprise Value	4.27M	PEG	-	EPS next Q	-	Inst Own	9.29%	Short Float	0.19%	Perf Quarter	-48.65%
Income	-6.22M	P/S	-	EPS this Y	-	Inst Trans	0.33%	Short Ratio	0.39	Perf Half Y	-51.84%
Sales	0.00M	P/B	1.91	EPS next Y	-	ROA	-75.43%	Short Interest	0.01M	Perf YTD	11.21%
Book/sh	1.30	P/C	1.89	EPS next 5Y	-	ROE	-79.47%	52W High	10.40 -76.15%	Perf Year	-66.44%
Cash/sh	1.31	P/FCF	-	EPS past 3/5Y	32.81% 36.13%	ROIC	-131.42%	52W Low	2.15 15.56%	Perf 3Y	-38.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	14.73% -0.26%	Gross Margin	-	Volatility	3.80% 7.20%	Perf 5Y	-91.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	35.59%	Oper. Margin	-207100.00%	ATR (14)	0.18	Perf 10Y	-99.57%
Dividend Ex-Date	-	Quick Ratio	19.97	Sales Y/Y TTM	-99.97%	Profit Margin	-207333.33%	RSI (14)	38.78	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.97	EPS Q/Q	66.10%	SMA20	-2.63%	Beta	1.70	Target Price	10.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	-18.96%	Rel Volume	0.49	Prev Close	2.49
Employees	2	LT Debt/Eq	0.00	Earnings	Oct 16 BMO	SMA200	-51.43%	Avg Volume	18.14K	Price	2.48
IPO	Mar 21, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	8,913	Change	-0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-18	Initiated	H.C. Wainwright	Buy	$5

Dec-18-25 08:05AM	Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives (PR Newswire) -8.15%
Oct-16-25 08:05AM	Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets (PR Newswire)
Aug-06-25 08:05AM	Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets (PR Newswire)
May-15-25 08:05AM	Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets (PR Newswire) +6.55%
Mar-21-25 08:05AM	Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets (PR Newswire)
08:00AM	Loading…
Jan-22-25 08:00AM	Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain (GlobeNewswire)
Nov-13-24 09:00AM	Pulmatrix and Cullgen Announce Proposed Merger (PR Newswire) +73.66%
Nov-08-24 10:26AM	Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-13-24 09:05AM	Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-29-24 08:45AM	Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation (PR Newswire)
May-15-24 09:35AM	Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) (PR Newswire)
May-10-24 01:53PM	PULM Stock Earnings: Pulmatrix Reported Results for Q1 2024 (InvestorPlace)
08:05AM	Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Mar-28-24 10:54PM	PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +8.02%
09:05AM	Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update (PR Newswire)
09:00AM	Loading…
Jan-08-24 09:00AM	Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives (PR Newswire)
Nov-09-23 09:05AM	Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Sep-19-23 09:05AM	Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine (PR Newswire)
Aug-23-23 09:05AM	Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole (PR Newswire)
Aug-10-23 09:05AM	Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-11-23 09:05AM	Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine (PR Newswire)
Jun-15-23 09:20AM	Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society (PR Newswire)
May-24-23 09:05AM	Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention (PR Newswire)
May-12-23 09:05AM	Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-02-23 09:05AM	Pulmatrix Supports World Asthma Day 2023 (PR Newswire)
Mar-30-23 09:05AM	Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update (PR Newswire)
Feb-06-23 09:10AM	Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma (PR Newswire)
Jan-25-23 09:05AM	Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" (PR Newswire) +10.16%
Jan-23-23 09:05AM	Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (PR Newswire)
Jan-04-23 09:05AM	Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine (PR Newswire) -12.44%
09:05AM	Loading…
Nov-10-22 09:05AM	Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Sep-26-22 09:00AM	Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine (PR Newswire)
Aug-08-22 09:05AM	Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-12-22 09:00AM	Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine (PR Newswire)
May-12-22 09:05AM	Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-22 09:05AM	Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update (PR Newswire)
Mar-21-22 08:05AM	Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD (PR Newswire)
Mar-17-22 04:05PM	Pulmatrix Regains Compliance With Nasdaq Listing Requirements (PR Newswire)
Mar-01-22 09:31AM	PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today? (InvestorPlace) -7.35%
09:00AM	Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline (PR Newswire)
Feb-24-22 04:05PM	Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split (PR Newswire) -14.82%
Feb-02-22 11:28AM	When Will Pulmatrix, Inc. (NASDAQ:PULM) Turn A Profit? (Simply Wall St.)
Feb-01-22 09:00AM	Pulmatrix Issues Letter to Stockholders (PR Newswire)
Dec-17-21 04:30PM	Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering (PR Newswire) -7.37%
Dec-15-21 08:00AM	Pulmatrix Announces $6.75 Million Registered Direct Offering (PR Newswire) -31.58%
Nov-17-21 03:01AM	These 40 Mass. companies made the new Deloitte Fast 500 list (American City Business Journals)
Nov-10-21 04:15PM	Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Nov-09-21 09:00AM	Pulmatrix Announces Resolution of Contract Dispute with Cipla (PR Newswire)
Nov-04-21 03:01PM	Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-02-21 02:20PM	Pulmatrix (NASDAQ:PULM) adds US$10m to market cap in the past 7 days, though investors from five years ago are still down 89% (Simply Wall St.)
Aug-14-21 03:57AM	Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts (Simply Wall St.)
Aug-10-21 09:10AM	Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
04:38AM	Companies Like Pulmatrix (NASDAQ:PULM) Are In A Position To Invest In Growth (Simply Wall St.)
Jul-30-21 03:00PM	Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to Decline (Zacks)
Jul-27-21 10:00AM	Pulmatrix appoints Director Anand Varadan (PR Newswire)
May-11-21 04:35PM	Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update (PR Newswire)
Apr-15-21 09:15AM	Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine (PR Newswire) -9.17%
Apr-12-21 05:41PM	Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio (PR Newswire) -16.28% -8.98%
09:00AM	Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio (PR Newswire)
Mar-23-21 09:05AM	Pulmatrix Reports 2020 Financial Results and Provides Business Update (PR Newswire) -7.43%
Mar-04-21 09:15AM	Pulmatrix Provides a Pipeline and Business Update (PR Newswire) -17.09%
Feb-16-21 01:30PM	Pulmatrix Announces Closing of $40 Million Registered Direct Offering (PR Newswire)
Feb-11-21 12:24AM	Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules (PR Newswire) -24.15%
Nov-12-20 09:00AM	Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates (PR Newswire)
Nov-09-20 01:39PM	Pulmatrix (NASDAQ:PULM) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Oct-21-20 09:00AM	Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud (PR Newswire)
Sep-30-20 08:30AM	Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles (PR Newswire)
Sep-29-20 08:30AM	Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore (PR Newswire) +5.31%
Sep-22-20 08:30AM	Pulmatrix Reports Progress on Product Pipeline (PR Newswire)
Aug-07-20 09:00AM	Pulmatrix Reports Q2 2020 Results and Business Updates (PR Newswire)
Jul-08-20 08:30AM	Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles (PR Newswire) +6.04%
Jun-26-20 09:00AM	Pulmatrix Announces Changes to Board of Directors (PR Newswire)
May-27-20 09:00AM	Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually (PR Newswire)
May-14-20 09:00AM	Pulmatrix Reports Q1 2020 Results (PR Newswire)
Apr-29-20 10:02AM	Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks (TipRanks) +8.21%
Apr-16-20 05:25PM	Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules (PR Newswire) +5.99% -29.38%
08:30AM	Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19 (PR Newswire)
Mar-26-20 09:00AM	Pulmatrix Reports 2019 Financial Results and Provides Business Update (PR Newswire) -11.57%
Jan-31-20 07:20AM	The Wining Sector & Its Top Stocks in Virus-Infected January (Zacks)
Jan-30-20 08:00AM	Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA (PR Newswire)
Jan-16-20 12:05PM	Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jan-06-20 08:58AM	Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies (PR Newswire) +5.30%
Jan-03-20 09:55AM	Pulmatrix Surges on License Agreement With Johnson & Johnson (Zacks) -6.79%
Jan-02-20 08:51AM	Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson (PR Newswire) +88.37%
Nov-04-19 09:15AM	Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors (PR Newswire)
Nov-01-19 09:00AM	Pulmatrix Reports Q3 2019 Results (PR Newswire)
Sep-18-19 09:30AM	Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma (PR Newswire)
Aug-19-19 09:25AM	Pulmatrix Receives US Patent Covering iSPERSE Formulations for Pulmazole Program (PR Newswire)
Aug-05-19 09:00AM	Pulmatrix Reports Q2 2019 Results (PR Newswire)
Jun-07-19 10:25AM	Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix (Zacks)
Jun-06-19 06:42AM	Bet on 5 Top Stocks With Rising P/E (Zacks)
May-16-19 09:10AM	Pulmatrix Announces Leadership Change (PR Newswire)
May-15-19 09:00AM	Pulmatrix Reports Q1 2019 Results (PR Newswire)
Apr-15-19 09:00AM	Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole (PR Newswire)
Apr-08-19 04:29PM	Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering (PR Newswire)
Apr-03-19 09:30PM	Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering (PR Newswire) -22.77% -23.08%
Apr-01-19 05:33PM	Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal (InvestorPlace) +81.89% -12.55%
02:34PM	Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment (MarketWatch)
09:00AM	Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole (PR Newswire)
Mar-14-19 09:45AM	Pulmatrix to Participate in Upcoming Investor Conferences (PR Newswire) +19.01%

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PULM

Pulmatrix Inc

Upgrade your FINVIZ experience